International Clinical Trial: A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07128251) titled 'A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)' on Aug. 13.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Anhui Provincial Hospital

Condition: Hepatocellular Carcinoma (HCC) Immunotherapy PD-1 CTLA-4 TACE

Intervention: Procedure: TACE treatment Drug: Iparomlimab and Tuvonralimab...